Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03419442 · ClinicalTrials.gov registry record
Multi-academic Center Study of Xofigo Patients
A clinical trial, sponsored by Bayer.
- Completed
- Registry status
- 150
- Enrollment target
NCT03419442 is a clinical trial that has completed, run by Bayer. The registered enrollment target is 150 participants.
The verdict
NCT03419442 has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- 150 participants
- Enrollment target
Study Summary
The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving radium-223 and chemotherapy. While clinical trials of radium-223 has demonstrated a survival benefit in the treatment of mCRPC, both pre and post- docetaxel, study lacked exposure to second generation androgens and hence could not assess outcomes pre or post abiraterone or enzalutamide. The specific objective of this study is to describe and compare the clinical outcomes between treatment sequences for patients with mCRPC where 1) radium-223 is used (alone or in combination with abiraterone or enzalutamide) prior to chemotherapy versus 2) radium-223 used after chemotherapy in the treatment of mCRPC. The secondary objectives are to describe the safety patterns of docetaxel use among mCRPC patients who received chemotherapy post radium-223.
Interventions
- DRUG Taxotere
- DRUG Xofigo
- DRUG Jevtana
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2018-12-03 |
| Est. Completion | 2019-10-22 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03419442
The ClinicalTrials.gov registry entry for NCT03419442 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Taxotere is the first listed.
NCT03419442 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03419442 about?
NCT03419442 is a clinical study titled "Multi-academic Center Study of Xofigo Patients". The study will be conducted from a real-world perspective to describe treatment sequences involving radium-223 and chemotherapy in patients with metastatic castrate resistant prostate cancer (mCRPC) and assess overall survival (OS) associated with treatment sequences involving radium-223 and chemoth...
What is the current status of trial NCT03419442?
This trial is currently completed. The enrollment target is 150 participants. The study started on 2018-12-03. Estimated completion is 2019-10-22.
What interventions are being tested in trial NCT03419442?
The interventions under investigation include: Taxotere (DRUG), Xofigo (DRUG), Jevtana (DRUG).
Who is sponsoring clinical trial NCT03419442?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.